🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06733766
Recruiting Observational

Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer

NCT06733766 · tracked via the Priya Life Science China tracker
Sponsor
Chinese PLA General Hospital
Phase
Observational
Started
2024-12-09
Last updated
2025-02-14

Condition(s) studied

Recurrent Thyroid Cancer

Investigational drug(s) / intervention(s)

ultrasound-guided thermal ablation

ultrasound-guided thermal ablation: microwave ablation, radiofrequency ablation, laser ablation

Study summary

To evaluate the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. patient received thyroidectomy for thyroid cancer 2. recurrent lesions were pathologically proven to be malignant by core-needle biopsy or fine needle aspiration 3. no evidence of distant metastases. 4. follow-up period ≥12 months Exclusion Criteria: 1. coagulation disorder, serious heart, respiratory, liver, or renal failure 2. dysfunction of the vocal cord on the opposite side

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chinese PLA General Hospital Beijing Beijing Municipality Recruiting

More Chinese PLA General Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06733766 on ClinicalTrials.gov ↗ ← All trials in China